CHEST Guidelines-Response_chest

Response_chest_22 (1)

Pdf Summary

The correspondence is a professional exchange between Dr. Suresh Kumar Angurana and Dr. Khalid Alansari, discussing a clinical study on the use of intravenous magnesium sulfate for treating bronchiolitis, as initially reported by Alansari and colleagues. The letter thanks Drs. Angurana and Kumar for their interest in the research, and it focuses on the treatments administered to study patients, which included nebulized epinephrine and saline given at intervals. The inclusion criteria for the study involved children with clinically apparent bronchiolitis, noting that many had an atopic background with conditions like eczema or a family history of asthma. This inclusion was critical, as excluding these children would have omitted many potential beneficiaries of the treatment. The study observed that 66% of young infants with bronchiolitis had eczema or a family history of asthma in previous research, and this number was 50% in their study, reinforcing the prevalence of these conditions.<br /><br />Dr. Alansari is affiliated with the Sidra Medical and Research Centre, Hamad Medical Corporation, and Weill Cornell Medical College, while Dr. Davidson is associated with the University of Washington School of Medicine. The dialogue captures the importance of inclusive criteria in clinical trials and acknowledges the complexity of treating bronchiolitis in infants with contributing health backgrounds. The letter concludes with standard professional courtesy, reaffirming the accuracy and collaborative spirit of clinical research and published findings.

Keywords

intravenous magnesium sulfate

bronchiolitis treatment

nebulized epinephrine

clinical study

atopic background

asthma family history

inclusive criteria

infant eczema

Sidra Medical

collaborative research